Semaglutide·Novo Nordisk·Oral tablet

Rybelsus

Rybelsus is a once-daily oral semaglutide tablet manufactured by Novo Nordisk, FDA-approved in September 2019 for the treatment of type 2 diabetes. It was the first GLP-1 receptor agonist available in pill form, eliminating the need for injections. While Rybelsus is approved for diabetes management rather than weight loss, it produces modest weight reduction of 5-10% of body weight and is commonly prescribed off-label for patients who prefer an oral medication over weekly injections. At Weight Method, semaglutide treatment starts at $154/month.

3mg7mg14mgOnce daily
Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Rybelsus is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated June 2026Medically reviewed by licensed providers

Rybelsus (semaglutide) is an FDA-approved GLP-1 medication for weight loss; in trials of the brand-name product, patients lost an average of 15-22% of their body weight. Weight Method does not dispense brand-name Rybelsus — it offers compounded semaglutide, prescribed by licensed providers, from $199/month with virtual consultations and direct shipping.

Key Fact

Rybelsus is the only oral GLP-1 medication available — a daily semaglutide tablet (3mg, 7mg, or 14mg) FDA-approved for type 2 diabetes in September 2019. Weight loss is modest compared to injectable semaglutide: approximately 5-7% of body weight.

Source: PIONEER clinical trial program

How does this medication work?

Rybelsus delivers semaglutide orally using SNAC absorption technology. Once absorbed, it activates GLP-1 receptors to reduce appetite, slow gastric emptying, and improve blood sugar control.

Rybelsus delivers semaglutide through an innovative oral formulation using an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), which protects the semaglutide peptide from stomach acid degradation and facilitates absorption through the stomach lining. Once absorbed, Rybelsus works identically to injectable semaglutide: it activates GLP-1 receptors in the brain to reduce appetite and food cravings, slows gastric emptying to extend satiety, and improves insulin secretion and blood sugar control. The oral bioavailability is lower than injectable forms, which is why Rybelsus doses (3mg, 7mg, 14mg) are measured differently than injection doses.

What is it FDA-approved for?

FDA-approved for type 2 diabetes (2019), the first oral GLP-1 receptor agonist. Prescribed off-label for modest weight loss in patients who prefer pills over injections.

Rybelsus is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is the first and, until Oral Wegovy's approval, was the only oral GLP-1 receptor agonist on the market. Rybelsus is not FDA-approved for weight management, but physicians may prescribe it off-label for weight loss in patients who are not candidates for or prefer to avoid injectable medications. The PIONEER clinical trial program demonstrated meaningful A1C reductions and moderate weight loss across diverse patient populations.

What are the key facts you should know?

Daily oral tablet, 3mg/7mg/14mg doses, must be taken on empty stomach with minimal water, PIONEER trials showed 5-10% weight loss, manufactured by Novo Nordisk.

Rybelsus is available in three dose strengths: 3mg, 7mg, and 14mg, taken once daily on an empty stomach with no more than 4 ounces of plain water, at least 30 minutes before the first food, beverage, or other oral medication of the day. In the PIONEER 1 trial, patients taking Rybelsus 14mg experienced an average weight loss of approximately 5-8 lbs over 26 weeks. The medication is manufactured by Novo Nordisk and was the first oral GLP-1 to receive FDA approval. Strict dosing requirements (empty stomach, limited water) are necessary to ensure adequate absorption of the semaglutide peptide.

Why choose this treatment?

Rybelsus is the only established oral semaglutide option, ideal for patients with needle aversion who want GLP-1 benefits without weekly injections.

Rybelsus® is the FDA-approved oral semaglutide product for type 2 diabetes — the first oral GLP-1 receptor agonist on the U.S. market. Patients seeking the FDA-approved brand-name Rybelsus® obtain it through a retail pharmacy. Weight Method does not dispense or prescribe brand-name Rybelsus®. Weight Method's compounded semaglutide program is dispensed by U.S.-licensed 503A compounding pharmacies at $154/month all-inclusive. Compounded semaglutide is not FDA-approved.

Ready to Get Started?

Answer a few quick questions to see if you qualify.

Check Eligibility

Your Treatment Options

Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.

Starting at$199/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Compounded semaglutide. Once-weekly subcutaneous injection.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Compounded tirzepatide. Dual-action GLP-1/GIP, once-weekly subcutaneous injection.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Rybelsus and Ozempic both contain semaglutide, but Rybelsus is an oral tablet taken daily while Ozempic is a weekly injection. Due to differences in absorption, Rybelsus delivers less semaglutide systemically, resulting in more modest weight loss (5-10% vs. 10-15%). Ozempic may be more effective for weight loss, but Rybelsus is preferred by patients who want to avoid injections entirely.

Rybelsus must be taken on an empty stomach first thing in the morning with no more than 4 ounces (half a glass) of plain water. Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. This strict protocol is essential because the SNAC absorption enhancer in Rybelsus requires specific stomach conditions to work properly. Taking it with food or other beverages significantly reduces absorption.

The most common side effects are nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation. These gastrointestinal effects are similar to injectable semaglutide and typically occur during the dose-escalation phase. Starting at the 3mg dose for 30 days before increasing helps minimize these effects. Serious but rare side effects include pancreatitis and diabetic retinopathy complications.

Yes, though the weight loss is more modest than injectable GLP-1 options. Patients on Rybelsus 14mg typically lose 5-10% of body weight over 6-12 months. If maximizing weight loss is your primary goal, your Weight Method provider may recommend an injectable compounded option instead. Rybelsus is best suited for patients who prioritize convenience and needle-free treatment.

No. Weight Method does not dispense or prescribe brand-name Rybelsus®. Our prescribing providers issue patient-specific prescriptions for compounded semaglutide. Weight Method's compounded semaglutide program is $154/month all-inclusive. Compounded semaglutide is not FDA-approved.

Rybelsus is FDA-approved for type 2 diabetes at doses up to 14mg daily, while Oral Wegovy is FDA-approved for chronic weight management at much higher doses (25mg and 50mg daily). Oral Wegovy uses a next-generation oral formulation that achieves significantly higher semaglutide levels, producing weight loss comparable to injectable Wegovy. If weight loss is your primary goal, Oral Wegovy is the more effective oral option.

Start Your Treatment

Speak with a licensed provider today and find out if GLP-1 medications are right for you.

Get Started Now

Free consultation. No commitment.

More about Rybelsus

Rybelsus Side EffectsRybelsus ResultsRybelsus Dosingsemaglutide Dosage Calculator

Generic Medication

Semaglutide

Other Semaglutide Brands

OzempicWegovyOral WegovySemaglutide

Compare Rybelsus

Rybelsus vs Oral WegovyRybelsus vs Ozempic

Rybelsus by State

Rybelsus in AlabamaRybelsus in AlaskaRybelsus in ArizonaRybelsus in ArkansasRybelsus in CaliforniaRybelsus in Colorado